| ¿µ¹® | nervous system | ÇÑ±Û | ½Å°æ°è |
|---|---|---|---|
| ¼³¸í | ¿©·¯ ±â°üµéÀÇ ¼·Î°£ »óÈ£¿¬°áü°è°¡ ¹Ù·Î ½Å°æ°èÀÌ´Ù. ¿©±â¿¡´Â ÁßÃ߽Űæ°è(central nerve system: CNS)¿Í ¸»ÃʽŰæ°è(peripheral nerve system: PNS)°¡ Àִµ¥, ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö¸¦ ¸»ÇÑ´Ù. ±×¸®°í ¸»ÃʽŰæ°è¿¡´Â 12½ÖÀÇ ³ú½Å°æ(cranial nerve: ³ú¿¡¼ ±â½ÃÇÏ¿© ÁÖ·Î ¾ó±¼ºÎÀ§¿Í ¸ñ ºÎÀ§¿¡ ºÐÆ÷ÇÑ´Ù)°ú 31½ÖÀÇ Ã´¼ö½Å°æ(spinal nerve:spinal cord¿¡¼ °¢±â ¾çÂÊÀ¸·Î ½ÖÀ» ÀÌ·ç¾î ³ª¿À´Âµ¥ ÁÖ·Î ¸ñÀÌÇϺÎÀ§ÀÇ ½Åü °¢ºÎºÐÀ¸·Î ºÐÆ÷ÇÏ°Ô µÈ´Ù)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¶ÇÇÑ ¸»ÃʽŰæ°è´Â 3°¡ÁöÀÇ ½Å°æÁ¶Á÷µé·Î ±¸¼ºµÇ¾î Àִµ¥ ¾Õ¿¡¼ ¸»ÇÑ ³ú½Å°æ°ú ô¼ö½Å°æ¿Ü¿¡ ÀÚÀ²½Å°æ°è°¡ ¿©±â¿¡ ÇØ´çµÈ´Ù. ÀÚÀ²½Å°æ°è´Â ´Ù½Ã ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀ¸·Î ³ª´µ¾îÁ® ¼·Î°£ÀÇ ¿Ã¹Ù¸¥ »óÈ£ÀÛ¿ëÀ¸·Î »ýü ¿©·¯ °¡Áö ÀÛ¿ëÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | cardiovascular system | ÇÑ±Û | ½ÉÀåÇ÷°ü°è |
|---|---|---|---|
| ¼³¸í | ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇÏ´Â ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼ À̸£´Â ¸»ÀÌ´Ù. |
||
| ¿µ¹® | autonomic nervous system | ÇÑ±Û | ÀÚÀ²½Å°æ°è |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ÀÇÁö¿Í °ü°è¾øÀÌ, ħÀ» È긮°Å³ª ¼Òȿ µî°ú °°Àº ½º½º·Î Á¶Á¤ÀÌ µÇ¾î ¿òÁ÷ÀÌ´Â ½Å°æ°èÀÌ¸ç ¿©±â¿¡´Â ´ÙÀ½°ú °°Àº µÎ °¡Áö°¡ ÀÖ´Ù. 1.±³°¨½Å°æ°è(sympathetic nervous system)-»ç¶÷ÀÌ À§Çè»óÅ¿¡ À̸£·¶À» °æ¿ì¿¡ ÈïºÐÀÌ µÇ´Â ÀÚÀ²½Å°æ°è. Áï ½É¹Ú¼öÀÇ Áõ°¡, ¼Òȱ⠿ÀÇ °¨¼Ò µîÀÇ ÀÏÀÌ À̰÷À» ÅëÇØ¼ ÀϾÙ. ±³°¨½Å°æÀÌ ÈïºÐµÇ¸é ±³°¨½Å°æÀÇ ¸»´Ü¿¡¼ epinephrine, norepinephrine µîÀÇ ¹°ÁúÀÌ ºÐºñµÇ°í À̰͵鿡 ÀÇÇØ¼ ¸»ÃÊÀå±â°¡ º¯È¸¦ ÀÏÀ¸Å²´Ù. ÇÏÁö¸¸ Àå±â¿¡ µû¶ó¼ epinephrineÀ̳ª norepinephrineÀÇ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ¾î¼ ¿©·¯ °¡Áö ´Ù¸¥ Àå±âÀÇ ¹ÝÀÀÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¼ö¿ëü´Â ´ÙÀ½°ú °°´Ù. -¾ËÆÄ¼ö¿ëü(alpha-receptor): ¸»ÃÊÇ÷°üÀÇ ¼öÃà, ±â°üÁöÀÇ ¼öÃà, µ¿°øÀÇ ±ÙÀ°ÀÇ ¼öÃà -º£Å¸1¼ö¿ëü(beta 1-receptor): ½ÉÀå¿¡ Á¸ÀçÇÏ´Â ¼ö¿ëü, ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. -º£Å¸2¼ö¿ëü(beta 2-receptor): Ç÷°üÀÇ ÀÌ¿Ï, ±â°üÁöÀÇ ÀÌ¿Ï, Áï °¢ Àå±âµéÀº ±× Àå±â°¡ °¡Áö°í ÀÖ´Â ±³°¨½Å°æÀÇ ¼ö¿ëü¿¡ µû¶ó ±³°¨½Å°æÀÇ ÈïºÐ(±³°¨½Å°æ ¸»´Ü¿¡¼ÀÇ epinephrineÀÇ ºÐºñ)¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ´Þ¶óÁø´Ù(¿¹-±³°¨½Å°æÀÌ ÈïºÐ½Ã¿¡ beta 1-¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Â ½ÉÀåÀº »¡¸® ¶Ù°Ô µÈ´Ù. ±³°¨½Å°æ ÈïºÐ½Ã¿¡ µ¿°øÀÇ ±ÙÀ°ÀÌ ¼öÃàÇØ¼ µ¿°øÀÇ Å©±â°¡ Ä¿Áø´Ù) 2.ºÎ±³°¨½Å°æ°è(parasympathetic nervous system)-±³°¨½Å°æ°ú ¹Ý´ë·Î ÀÛ¿ëÇÑ´Ù. Áï »ç¶÷ÀÌ Á¹¸®°Å³ª ½¯ °æ¿ì¿¡ ÈïºÐÇÑ´Ù. ºÎ±³°¨½Å°æÀÌ ÈïºÐÇÒ ¶§¿¡´Â ½Å°æÀÇ ¸»´Ü¿¡¼ ¾Æ¼¼Ä¥Äݸ°ÀÇ ºÐºñ°¡ ÀϾ°í À̰ÍÀ¸·Î ÀÎÇØ¼ °¢ Àå±âÀÇ º¯È°¡ ÀϾÙ. |
||
| ¿µ¹® | TNM staging system | ÇÑ±Û | Á¾¾çº´±âºÐ·ù°èÅë |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤ÇÏ´Â ÇÑ ¹æ¹ý. T´Â Tumor(Á¾¾ç)¸¦ ¶æÇÏ¸ç ¿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀÇ Ä§À±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î ħÀ±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù. NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç ħ¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù. MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇÏ¸ç ¿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù. ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀÎ º´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | central nervous system(CNS) | ÇÑ±Û | ÁßÃ߽Űæ°è |
|---|---|---|---|
| ¼³¸í | ½Å°æ°è´Â ÁßÃ߽Űæ°è¿Í ¸»ÃʽŰæ°è·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ´Ù. ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö·Î ±¸¼ºµÇ¾î ÀÖ´Â ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. ¸»ÃʽŰæ°è¶õ ÀÌ ÀÌ¿ÜÀÇ ¸ðµç ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. |
||
| RTD | renal tubular defect; routine test dilution |
|---|---|
| RAS | rapid atrial stimulation; recurrent aphthous stomatitis; reflex activating stimulus; reliability, av... |
| MDS | Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system... |
| MPS | meconium plug syndrome; medial premotor system; Member of the Pharmaceutical Society; microbial prof... |
| CRD | carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint... |
| lambdoid suture defect | <radiology> Well-defined lucent lesion, classically unilateral, associated with neurofibromatosis (12 Dec 1998) |
|---|---|
| luteal phase defect | Inadequate function of the corpus luteum that may prevent a fertilized egg from implanting in the uterus or may lead to early pregnancy loss. (09 Oct 1997) |
| acute renal failure | <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes. Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect). Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement. (27 Sep 1997) |
| aminoaciduria, renal | Impairment of renal tubular transport of amino acids. (12 Dec 1998) |
| back-pressure renal atrophy | <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids (12 Dec 1998) |
| base of renal pyramid | The outer broad part of a renal pyramid that lies next to the cortex. Synonym: basis pyramidis renis. (05 Mar 2000) |
| branchio-oto-renal syndrome | <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation. (12 Dec 1998) |
| capsular branches of renal artery | <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule. Synonym: rami capsulares arteriae renalis. (05 Mar 2000) |
| captopril renal scan | <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis (12 Dec 1998) |
| carcinoma, renal cell | Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural. (12 Dec 1998) |
| renal | <anatomy> Pertaining to the kidney, nephric. (18 Nov 1997) |
| renal adenocarcinoma | <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging (12 Dec 1998) |
| renal adenocarcinoma: staging | <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs (12 Dec 1998) |
| renal adenocarcinoma: vascularity | <radiology> 85% hypervascular (require pre-op embolization), 10% hypovascular (usually the papillary type), 5% avascular also: 10% are bilateral (12 Dec 1998) |
| renal agenesis | <radiology> Associated with, duplicated vagina and/or uterus (mullerian duct anomaly), seminal vesicle cysts (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|